UF startup Rise Therapeutics, a clinical-stage biotechnology company advancing novel oral immunotherapies for autoimmune diseases, announced the completion of full enrollment in the 4-week dose expansion cohort of its Phase 1b clinical trial (NCT05961592) evaluating orally dosed R-2487 in patients with active rheumatoid arthritis (RA). Confirmation of the drug free, durability of clinical response marks a key inflection point in the program’s clinical development.
The multi-center U.S. clinical trial is evaluating R-2487 in patients with active RA in combination with standard of care, targeting intervention before patients begin treatment with biologics or JAK inhibitors.
Read more about Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial.
